company background image
EMD logo

Emyria CHIA:EMD Stock Report

Last Price

AU$0.033

Market Cap

AU$13.7m

7D

-2.9%

1Y

-59.8%

Updated

04 Nov, 2024

Data

Company Financials

EMD Stock Overview

Engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia.

EMD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Emyria Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Emyria
Historical stock prices
Current Share PriceAU$0.033
52 Week HighAU$0.087
52 Week LowAU$0.027
Beta0.81
11 Month Change-2.94%
3 Month Change-13.16%
1 Year Change-59.76%
33 Year Change-90.00%
5 Year Changen/a
Change since IPO-77.24%

Recent News & Updates

Recent updates

Shareholder Returns

EMDAU PharmaceuticalsAU Market
7D-2.9%-2.9%-0.6%
1Y-59.8%58.6%16.5%

Return vs Industry: EMD underperformed the Australian Pharmaceuticals industry which returned 61.9% over the past year.

Return vs Market: EMD underperformed the Australian Market which returned 16.1% over the past year.

Price Volatility

Is EMD's price volatile compared to industry and market?
EMD volatility
EMD Average Weekly Movement16.6%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement8.6%
10% most volatile stocks in AU Market17.8%
10% least volatile stocks in AU Market3.6%

Stable Share Price: EMD's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: EMD's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2018n/aMichael Winloemyria.com

Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson’s disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications. The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is under preclinical trial program; and provides psychological trauma care facility under the Pax Centre name.

Emyria Limited Fundamentals Summary

How do Emyria's earnings and revenue compare to its market cap?
EMD fundamental statistics
Market capAU$13.71m
Earnings (TTM)-AU$11.46m
Revenue (TTM)AU$2.20m

6.2x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EMD income statement (TTM)
RevenueAU$2.20m
Cost of RevenueAU$2.37m
Gross Profit-AU$167.55k
Other ExpensesAU$11.29m
Earnings-AU$11.46m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.028
Gross Margin-7.61%
Net Profit Margin-520.07%
Debt/Equity Ratio33.5%

How did EMD perform over the long term?

See historical performance and comparison